Mallinckrodt plc, the drugmaker spun off by Covidien plc, agreed to buy Cadence Pharmaceuticals Inc. for about $1.3 billion to add a pain treatment used in hospitals.

Mallinckrodt will begin a tender offer for Cadence shares at $14 each, the companies said in a statement today. The price is 26 percent above Cadence’s closing level yesterday in Nasdaq trading.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.